SCHEDULE 13G 0002077247 XXXXXXXX LIVE Common Stock, par value $0.01 per share 08/29/2025 0001641489 vTv Therapeutics Inc. 918385204 3980 Premier Dr Suite 310 High Point NC 27265 Rule 13d-1(c) Trails Edge Capital Partners, LP DE 340536.00 0.00 340536.00 0.00 340536.00 N 9.9 IA PN See Item 4 for additional information. Trails Edge Biotechnology Master Fund, LP E9 340536.00 0.00 340536.00 0.00 340536.00 N 9.9 PN See Item 4 for additional information. Ortav Yehudai X1 340536.00 0.00 340536.00 0.00 340536.00 N 9.9 IN See Item 4 for additional information. vTv Therapeutics Inc. 3980 Premier Dr, Suite 310 High Point, NC 27265 This report on Schedule 13G is being filed by Trails Edge Capital Partners, LP, a Delaware limited partnership ("Trails Edge Capital"). Trails Edge Capital is the investment manager to Trails Edge Biotechnology Master Fund, LP, a Cayman Islands limited partnership ("Trails Edge Biotechnology") and Ortav Yehudai ("Mr. Yehudai"), the Chief Investment Officer of Trails Edge Capital. Each of Trails Edge Capital, Trails Edge Biotechnology and Mr. Yehudai are referred to individually as a "Filer" and collectively as the "Filers". The address for each Filer is 3455 Peachtree Road NE, 5th Floor, Atlanta, GA 30326. See Item 4 of the cover page of each Filer. Y As of August 29, 2025, each Filer may be deemed to beneficially own an aggregate of 340,536 shares of Class A common stock (the "Common Stock"), par value $0.01 (the "Shares"), of vTv Therapeutics Inc. (the "Issuer"). The 340,536 Shares reported as beneficially owned on this Schedule 13G by each Filer consists of the following: (i) 231,000 Shares held directly by Trails Edge Biotechnology, and (ii) 109,536 Shares underlying prefunded warrants (the "Pre-Funded Warrants") held directly by Trails Edge Biotechnology. The securities beneficially owned by each Filer excludes (i) 314,835 Shares underlying Pre-Funded Warrants, and (ii) 655,371 Shares underlying warrants (the "Common Warrants" and, together with the Pre-Funded Warrants, the "Warrants"), each of which contain an issuance limitation that prohibits the holder from exercising the Warrants to the extent that after giving effect to such issuance after the exercise, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates, including the other Filers) would beneficially own in excess of 9.99% of the Shares outstanding immediately after giving effect to the issuance of the Shares issuable upon exercise of the Warrants. As a result, Trails Edge Biotechnology beneficially owns 9.9% of the outstanding Shares of the Issuer as of August 29, 2025 (the "Event Date"). Trails Edge Capital, as the investment manager to Trails Edge Biotechnology, may be deemed to beneficially own these securities. Mr. Yehudai, as the Chief Investment Officer of Trails Edge Capital, exercises voting and investment discretion with respect to these securities and as such may be deemed to beneficially own 9.9% of the outstanding Shares of the Issuer as of the Event Date. Ownership percentages are based on (i) 2,617,215 shares of Common Stock issued and outstanding as of August 12, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, filed with the Securities and Exchange Commission on August 12, 2025, and (ii) 682,018 shares of Common Stock issued subsequent to August 12, 2025 as disclosed by the Issuer. 9.9% % 340,536 0 340,536 0 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 1 - Joint Filing Agreement Trails Edge Capital Partners, LP By: Trails Edge Capital Partners, LLC, GP of Trails Edge Capital Partners, LP /s/ Ortav Yehudai 09/08/2025 Trails Edge Biotechnology Master Fund, LP By: Trails Edge GP, LLC, GP of Trails Edge Biotechnology Fund GP, LP, GP of Trails Edge Biotechnology Master Fund, LP /s/ Ortav Yehudai 09/08/2025 Ortav Yehudai /s/ Ortav Yehudai 09/08/2025